Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where H. Michael Belmont is active.

Publication


Featured researches published by H. Michael Belmont.


Arthritis & Rheumatism | 2008

Abetimus sodium for renal flare in systemic lupus erythematosus: Results of a randomized, controlled phase III trial†

Mario H. Cardiel; James A. Tumlin; Richard A. Furie; Daniel J. Wallace; Tenshang Joh; Matthew D. Linnik; Micha Abeles; Jacob Aelion; Gerald B. Appel; Cynthia Aranow; Stanley P. Ballou; Michael Becker; H. Michael Belmont; Eugene P. Boling; Stefano Bombardieri; James P. Brodeur; Jill P. Buyon; John J. Condemi; Mary E. Cronin; John J. Cush; Raphael J. Dehoratius; Deborah Desir; John Donohue; Michael Edwards; Mohamed A. El-Shahawy; Paul Emery; Stephanie Ensworth; Luis R. Espinoza; Maria Fondal; Paul R. Fortin

OBJECTIVE To investigate whether treatment with abetimus delays renal flare in patients with lupus nephritis. Secondary objectives included evaluation of the effect of abetimus on C3 levels, anti-double-stranded DNA (anti-dsDNA) antibody levels, use of high-dose corticosteroids and/or cyclophosphamide, and major systemic lupus erythematosus (SLE) flare. METHODS We conducted a randomized, placebo-controlled study of treatment with abetimus at 100 mg/week for up to 22 months in SLE patients. Three hundred seventeen patients with a history of renal flare and anti-dsDNA levels >15 IU/ml were randomized to a treatment group (158 abetimus, 159 placebo); 298 (94%) were enrolled in the intent-to-treat (ITT) population (145 abetimus, 153 placebo), based on the presence of high-affinity antibodies for the oligonucleotide epitope of abetimus at baseline screening. RESULTS Abetimus did not significantly prolong time to renal flare, time to initiation of high-dose corticosteroid and/or cyclophosphamide treatment, or time to major SLE flare. However, there were 25% fewer renal flares in the abetimus group compared with the placebo group (17 of 145 abetimus-treated patients [12%] versus 24 of 153 placebo-treated patients [16%]). Abetimus treatment decreased anti-dsDNA antibody levels (P < 0.0001), and reductions in anti-dsDNA levels were associated with increases in C3 levels (P < 0.0001). More patients in the abetimus group experienced > or =50% reductions in proteinuria at 1 year, compared with the placebo group (nominal P = 0.047). Trends toward reduced rates of renal flare and major SLE flare were noted in patients treated with abetimus who had impaired renal function at baseline. Treatment with abetimus for up to 22 months was well tolerated. CONCLUSION Abetimus at 100 mg/week significantly reduced anti-dsDNA antibody levels but did not significantly prolong time to renal flare when compared with placebo. Multiple positive trends in renal end points were observed in the abetimus treatment group.


Lupus | 1995

New York University/Hospital for Joint Diseases experience with intravenous cyclophosphamide treatment: efficacy in steroid unresponsive lupus nephritis

H. Michael Belmont; Marc Storch; Jill P. Buyon; Steven B. Abramson

The medical records of patients receiving cyclophosphamide for lupus nephritis between 1987 and 1993 at the New York University/Hospital for Joint Diseases Lupus Study Group Institutions were retrospectively reviewed. We identified 45 patients (38 female, seven male) who received a mean of 9 ± 1 (range 2-23) pulses of intravenous cyclophosphamide for diffuse proliferative glomerulone phritis (n = 28), focal proliferative glomerulonephritis (n = 7), membranous nephropathy (n = 5), mesangial nephropathy with sclerosis (n = 1) or nephritis without biopsy (n = 4). Forty-two of the 45 patients received cyclophosphamide after failing steroid therapy. During a follow-up period of 52 ± 3 months, nine patients progressed to end-stage renal disease (ESRD) with three additional patients experiencing a doubling of the creatinine and two patients persistent nephrotic range proteinuria. There were no deaths directly attributable to cyclophosphamide and no patients developed hemorrhagic cystitis or malignancy. Ten of 37 women had ceased menstruating prior to cyclophosphamide therapy. Treatment-associated amenorrhea occurred in only three patients all over 27 years of age. Intermittent intravenous cyclophosphamide therapy of lupus nephritis is well tolerated and usually effective in maintaining renal function in patients unresponsive to steroids although, in our experience, 20% of patients developed ESRD and a total of 14 of 45 (30%) patients had unsatisfactory outcomes.


Jcr-journal of Clinical Rheumatology | 1995

Can women with systemic lupus erythematosus safely use exogenous estrogens

Jill P. Buyon; Kenneth C. Kalunian; Mary Louise Skovron; Michelle Petri; Robert G. Lahita; Joan T. Merrill; Lisa R. Sammaritano; Christianne Yung; F. Licciardi; H. Michael Belmont; Bevra H. Hahn

The current study was initiated to estimate the use of oral contraceptives and estrogen replacement therapy in women with systemic lupus erythematosus (SLE). Four hundred and four patients were surveyed from five medical centers. Two hundred and twenty four (55%) had ever used oral contraceptives, however, only 51 (13%) were taking oral contraceptives at the time SLE was diagnosed. Fifty five (14%) used oral contraceptives after their disease was diagnosed. Only seven (13%) reported an exacerbation of disease activity, mostly confined to the musculoskeletal system. In one substudy, there were no significant differences observed between women with or without SLE with regard to the frequency of ever-use of oral contraceptives. In contrast, significantly fewer women with established SLE were taking oral contraceptives at the time of interview compared with healthy women, p < 0.02. In a second substudy, information on past and present usage of estrogen replacement therapy was obtained in women followed at two of the sites included in the main study. Fifty-five (59%) of the 94 postmenopausal patients at these centers had ever taken estrogen therapy, 23 (24%) at the time of diagnosis. Forty-eight women (51%) began or remained on estrogen therapy after the diagnosis of SLE, four (8%) of whom reported exacerbations of disease activity. A significantly higher percentage of Caucasian women had taken or were taking estrogen replacement compared with other ethnic groups. This study suggests that exogenous hormones were generally well tolerated by women with SLE; this preliminary observation is based on patient recall. The low frequency of current oral contraceptive use in lupus patients of reproductive age may reflect, in part, bias of the managing rheumatologists and obstetricians/gynecologists. Given the health needs of and potential benefits for women with SLE, these observations suggest that larger prospective studies are critical and are likely to change prescribing practices for exogenous estrogen.


The Journal of Rheumatology | 2008

Use of Pharmacogenetics, Enzymatic Phenotyping, and Metabolite Monitoring to Guide Treatment with Azathioprine in Patients with Systemic Lupus Erythematosus

Anca Askanase; Daniel J. Wallace; Michael H. Weisman; Chung-E Tseng; Lana Bernstein; H. Michael Belmont; Ernest Seidman; Mariko L. Ishimori; Peter M. Izmirly; Jill P. Buyon

Objective. Individualized therapy based on genetic background and monitoring of metabolites can optimize drug safety and efficacy. Such an approach is available for azathioprine (AZA), the thiopurine antimetabolite. AZA exerts therapeutic effects when metabolized to the active thiopurine nucleotide, 6-thioguanine (6-TGN). In inflammatory bowel disease (IBD), 6-TGN levels in the target range of 235–400 pmol/8 ×108 red blood cells (RBC) are associated with a high likelihood of response. Our objective was to evaluate whether drug escalation based on metabolite levels improves efficacy and maintains safety in patients with systemic lupus erythematosus (SLE). Methods. We conducted a 6-month open-label dose-escalation clinical study of patients with active SLE treated with azathioprine dosed by body weight and metabolite levels. The primary endpoint was ≥50% improvement in any one parameter of disease activity, or 50% decrease in glucocorticoid dose. Results. Of 50 patients enrolled in the study, 21 achieved clinical responses, 13 of whom had 6-TGN < 235 pmol/8 ×108 RBC. Ten patients had no clinical response at 6 months, yet achieved either therapeutic IBD 6-TGN levels (> 235, n = 4) or received maximum AZA dose ≥3.5 mg/kg (n = 6). In 19 patients the drug was discontinued prematurely due to side effects or SLE activity. For those patients in whom either liver function test or white blood cell count abnormalities were encountered, metabolites guided attribution to drug or disease activity. Conclusion. Clinical responses in SLE can occur at levels of 6-TGN lower than the target range established for IBD. During followup, measurements of AZA metabolites may provide a rational approach to safety.


The Journal of Rheumatology | 2008

Current Therapies for Lupus Nephritis in an Ethnically Heterogeneous Cohort

Tania L. Rivera; H. Michael Belmont; Seema Malani; Melissa Latorre; Lauri Benton; Joseph Weisstuch; Laura Barisoni; Chung E. Tseng; Peter M. Izmirly; Jill P. Buyon; Anca Askanase

Objective. To evaluate responses to mycophenolate mofetil (MMF) and intravenous cyclophosphamide (CYC) in lupus nephritis in a multiethnic population. Methods. This was a retrospective study of all patients with systemic lupus erythematosus (SLE) that underwent kidney biopsy at New York University Medical Center. Patients with followup of at least 6 months were included. Clinical response was defined as complete (return to ± 10% of normal) or partial (improvement of 50% in abnormal renal measurements). Results. Ninty-nine patients were included in the study: 86% females, 86% non-Caucasian, age 34.2 ± 1.1 years, 62% with proliferative nephritis (PN; ISN/RPS-III and IV), and 32% with membranous nephritis (MN; ISN/RPS-V). Of the 70 patients with PN, 37 were treated with CYC and 33 with MMF. The baseline characteristics of the 2 treatment groups were different in the incidence of ISN/RPS-IV, values of serum creatinine and serum albumin, and type of insurance (p < 0.05). The response rate was greater in the MMF than in the CYC group (70% vs 41%). Responses to MMF were different in Asians (11/11), Caucasians (4/5), African Americans (3/5), and Hispanics (5/11). Responses to CYC had a similar distribution (Asians 6/10, Caucasians 4/5, African Americans 4/9, Hispanics 1/11). In the MN group (N = 23) responses were similar to the PN group (73% MMF and 38% CYC). After adjusting for race, serum creatinine, serum albumin, type of insurance, and class of nephritis, in a logistic regression model, response to MMF was superior to CYC: OR 6.2 (95% CI 1.9–20.2). Hispanics had worse outcome than Caucasians (OR 0.17). Longterm followup suggested no difference in maintenance with MMF or CYC. Conclusion. After controlling for the fact that less severe nephritis is preferentially treated with MMF, we found overall that response to MMF was superior to CYC. In this US population, ethnicity was observed to have an influence on response.


Radiology | 2009

Three-dimensional Electrocardiographically Gated Variable Flip Angle FSE Imaging for MR Angiography of the Hands at 3.0 T: Initial Experience

Ruth P. Lim; Pippa Storey; Iliyana P. Atanasova; Jian Xu; Elizabeth M. Hecht; James S. Babb; David R. Stoffel; Hugo Chang; KellyAnne McGorty; Qun Chen; Henry Rusinek; H. Michael Belmont; Vivian S. Lee

After institutional review board approval and informed consent were obtained for this HIPAA-compliant investigation, a three-dimensional electrocardiographically gated variable flip angle (VFA) fast spin-echo magnetic resonance (MR) angiography technique was evaluated as an unenhanced method for imaging hand arteries in 13 subjects (including four patients) at 3.0 T; this included evaluation of vessel visualization with warming and cooling in seven subjects. Examinations were evaluated for image quality and vessel conspicuity. Clear separation of arteries from veins was achieved in all subjects, with excellent vessel conspicuity and depiction of stenoses. Warming improved vessel visualization in healthy volunteers. VFA MR angiography is a high-spatial-resolution technique that enables the assessment of vascular reactivity in response to temperature challenge.


JCI insight | 2017

Single cell RNA sequencing to dissect the molecular heterogeneity in lupus nephritis

Saritha Ranabothu; Hemant Suryawanshi; Kemal Marc Akat; Robert R. Clancy; Pavel Morozov; Manjunath Kustagi; Mareike Czuppa; Peter M. Izmirly; H. Michael Belmont; Tao Wang; Nicole Jordan; Nicole Bornkamp; Janet Nwaukoni; July Martinez; Beatrice Goilav; Jill P. Buyon; Thomas Tuschl; Chaim Putterman

Lupus nephritis is a leading cause of mortality among systemic lupus erythematosus (SLE) patients, and its heterogeneous nature poses a significant challenge to the development of effective diagnostics and treatments. Single cell RNA sequencing (scRNA-seq) offers a potential solution to dissect the heterogeneity of the disease and enables the study of similar cell types distant from the site of renal injury to identify novel biomarkers. We applied scRNA-seq to human renal and skin biopsy tissues and demonstrated that scRNA-seq can be performed on samples obtained during routine care. Chronicity index, IgG deposition, and quantity of proteinuria correlated with a transcriptomic-based score composed of IFN-inducible genes in renal tubular cells. Furthermore, analysis of cumulative expression profiles of single cell keratinocytes dissociated from nonlesional, non-sun-exposed skin of patients with lupus nephritis also revealed upregulation of IFN-inducible genes compared with keratinocytes isolated from healthy controls. This indicates the possible use of scRNA-seq analysis of skin biopsies as a biomarker of renal disease. These data support the potential utility of scRNA-seq to provide new insights into the pathogenesis of lupus nephritis and pave the way for exploiting a readily accessible tissue to reflect injury in the kidney.


The Journal of Rheumatology | 2009

Systemic lupus erythematosus in 6 male cocaine users at Bellevue hospital.

Tania L. Rivera; H. Michael Belmont; Gerald Weissmann

To the Editor: Genetics, environment, and gender contribute to the pathogenesis of systemic lupus erythematosus (SLE). As in other autoimmune diseases, females are more often afflicted than males, with a ratio of 9:11. Sex hormones themselves have been held responsible for this imbalance, since SLE often flares during pregnancy and tends to remit after menopause2,3. The effect of cocaine on innate and acquired immunity has been extensively investigated. While cocaine modifies immune responses and is linked to an increased susceptibility to infections4, no association between cocaine use and the induction of SLE has been described. We describe 6 cases treated at the New York University Medical Center Bellevue Hospital, an institution often characterized as the “canary in the coal mine” of urban medicine5. In this tradition, we describe 6 men with SLE with chronic cocaine abuse and suggest possible mechanisms to explain an association between cocaine and SLE6. Patients’ characteristics are detailed in Table 1. Patient 1, a 25-year-old Hispanic man with a history of polysubstance abuse, including cocaine, was diagnosed with lupus nephritis that progressed to endstage renal disease … Address correspondence to Dr. T.L. Rivera, Department of Medicine, Division of Rheumatology, New York University School of Medicine, 301 East 17th Street, Room 1410, New York, NY 10003. E-mail: tania.rivera{at}nyumc.org.


Arthritis & Rheumatism | 2017

The Incidence and Prevalence of Systemic Lupus Erythematosus in New York County (Manhattan), New York: The Manhattan Lupus Surveillance Program

Peter M. Izmirly; Isabella Wan; Sara Sahl; Jill P. Buyon; H. Michael Belmont; Jane E. Salmon; Anca Askanase; Joan M. Bathon; Laura Geraldino-Pardilla; Yousaf Ali; Ellen M. Ginzler; Chaim Putterman; Caroline Gordon; Charles G. Helmick; Hilary Parton

The Manhattan Lupus Surveillance Program (MLSP) is a population‐based registry designed to determine the prevalence of systemic lupus erythematosus (SLE) in 2007 and the incidence from 2007 to 2009 among residents of New York County (Manhattan), New York, and to characterize cases by race/ethnicity, including Asians and Hispanics, for whom data are lacking.


Journal of Magnetic Resonance Imaging | 2015

3 Tesla MRI detects deterioration in proximal femur microarchitecture and strength in long-term glucocorticoid users compared with controls

Gregory Chang; Chamith S. Rajapakse; Ravinder R. Regatte; James S. Babb; Amit Saxena; H. Michael Belmont; Stephen Honig

Glucocorticoid‐induced osteoporosis (GIO) is the most common secondary form of osteoporosis, and glucocorticoid users are at increased risk for fracture compared with nonusers. There is no established relationship between bone mineral density (BMD) and fracture risk in GIO. We used 3 Tesla (T) MRI to investigate how proximal femur microarchitecture is altered in subjects with GIO.

Collaboration


Dive into the H. Michael Belmont's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Joan T. Merrill

Oklahoma Medical Research Foundation

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Mary E. Cronin

Medical College of Wisconsin

View shared research outputs
Top Co-Authors

Avatar

Michelle Petri

Johns Hopkins University School of Medicine

View shared research outputs
Top Co-Authors

Avatar

Bevra H. Hahn

University of California

View shared research outputs
Top Co-Authors

Avatar

Chaim Putterman

Albert Einstein College of Medicine

View shared research outputs
Researchain Logo
Decentralizing Knowledge